ArticleAmerican journal of respiratory and critical care medicine2018

Reply to D'Alessandro-Gabazza et al.: Risks of Treating Idiopathic Pulmonary Fibrosis with a TAM Receptor Kinase Inhibitor.

Milena S Espindola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.